Lord, Abbett & Co’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $117M | Sell |
929,682
-1,070,661
| -54% | -$141M | 0.34% | 80 |
|
|
2026
Q1 | $279M | Buy |
2,000,343
+791,141
| +65% | +$111M | 0.91% | 21 |
|
|
2025
Q4 | $148M | Buy |
1,209,202
+5,528
| +0.5% | +$672K | 0.46% | 58 |
|
|
2025
Q3 | $134M | Buy |
1,203,674
+80,489
| +7% | +$9.15M | 0.4% | 69 |
|
|
2025
Q2 | $125M | Sell |
1,123,185
-368,192
| -25% | -$39.2M | 0.4% | 71 |
|
|
2025
Q1 | $167M | Buy |
+1,491,377
| New | +$154M | 0.6% | 40 |
|
|
2023
Q2 | – | Sell |
-5,220
| Closed | -$433K | – | 549 |
|
|
2023
Q1 | $433K | Buy |
5,220
+10
| +0.2% | +$828 | ﹤0.01% | 529 |
|
|
2022
Q4 | $447K | Sell |
5,210
-23,740
| -82% | -$1.88M | ﹤0.01% | 561 |
|
|
2022
Q3 | $1.79M | Buy |
+28,950
| New | +$1.83M | 0.01% | 540 |
|
|
2020
Q2 | – | Sell |
-486,390
| Closed | -$36.4M | – | 661 |
|
|
2020
Q1 | $36.4M | Buy |
486,390
+180,452
| +59% | +$12.5M | 0.16% | 196 |
|
|
2019
Q4 | $19.9M | Sell |
305,938
-18,659
| -6% | -$1.22M | 0.07% | 389 |
|
|
2019
Q3 | $20.6M | Sell |
324,597
-2,858
| -0.9% | -$187K | 0.07% | 405 |
|
|
2019
Q2 | $22.1M | Sell |
327,455
-44,033
| -12% | -$2.9M | 0.07% | 403 |
|
|
2019
Q1 | $24.1M | Buy |
371,488
+47,600
| +15% | +$3.16M | 0.08% | 375 |
|
|
2018
Q4 | $20.3M | Sell |
323,888
-19,500
| -6% | -$1.36M | 0.07% | 390 |
|
|
2018
Q3 | $26.5M | Sell |
343,388
-80,050
| -19% | -$6.05M | 0.07% | 415 |
|
|
2018
Q2 | $30M | Buy |
423,438
+70,334
| +20% | +$4.97M | 0.09% | 366 |
|
|
2018
Q1 | $26.6M | Buy |
+353,104
| New | +$28.1M | 0.08% | 389 |
|
|
2017
Q4 | – | Sell |
-62,400
| Closed | -$5.06M | – | 874 |
|
|
2017
Q3 | $5.06M | Buy |
+62,400
| New | +$4.77M | 0.01% | 762 |
|
|
2017
Q1 | – | Sell |
-26,000
| Closed | -$1.86M | – | 881 |
|
|
2016
Q4 | $1.86M | Sell |
26,000
-130,505
| -83% | -$9.7M | 0.01% | 836 |
|
|
2016
Q3 | $12.4M | Buy |
156,505
+33,322
| +27% | +$2.71M | 0.04% | 521 |
|
|
2016
Q2 | $10.3M | Sell |
123,183
-50,592
| -29% | -$4.49M | 0.03% | 574 |
|
|
2016
Q1 | $16M | Buy |
173,775
+14,665
| +9% | +$1.32M | 0.05% | 470 |
|
|
2015
Q4 | $16.1M | Sell |
159,110
-234,392
| -60% | -$24.4M | 0.05% | 489 |
|
|
2015
Q3 | $38.6M | Buy |
393,502
+95,005
| +32% | +$10.6M | 0.12% | 277 |
|
|
2015
Q2 | $34.9M | Buy |
+298,497
| New | +$32.6M | 0.09% | 348 |
|
|
2015
Q1 | – | Sell |
-75,951
| Closed | -$7.16M | – | 920 |
|
|
2014
Q4 | $7.16M | Sell |
75,951
-253,104
| -77% | -$26.2M | 0.02% | 669 |
|
|
2014
Q3 | $35M | Buy |
329,055
+83,319
| +34% | +$8.16M | 0.09% | 322 |
|
|
2014
Q2 | $20.4M | Sell |
245,736
-1,763,998
| -88% | -$137M | 0.05% | 522 |
|
|
2014
Q1 | $142M | Sell |
2,009,734
-1,673,347
| -45% | -$131M | 0.32% | 84 |
|
|
2013
Q4 | $277M | Buy |
3,683,081
+3,457,566
| +1,533% | +$241M | 0.62% | 18 |
|
|
2013
Q3 | $14.2M | Buy |
225,515
+50,264
| +29% | +$3M | 0.03% | 584 |
|
|
2013
Q2 | $8.97M | Buy |
+175,251
| New | +$9.13M | 0.02% | 651 |
|
Other funds holding GILD
Lord, Abbett & Co's GILD Position: Q2 2026 in Review
Lord, Abbett & Co reduced its Gilead Sciences (GILD) stake by 54% in Q2 2026, selling an estimated $141M and leaving 929,682 shares worth $117M. The position accounts for 0.34% of the portfolio, ranked #80.
Lord, Abbett & Co first reported a position in GILD in Q2 2013 and has held it in 33 quarters since. The position peaked at $279M in Q1 2026. 2,268 funds tracked by Wall St. Rank hold GILD as of Q2 2026.
- Lord, Abbett & Co held 929,682 shares of Gilead Sciences worth $117M as of Q2 2026.
- Lord, Abbett & Co sold 1,070,661 Gilead Sciences shares in Q2 2026, an estimated $141M.
- Gilead Sciences made up 0.34% of Lord, Abbett & Co's portfolio in Q2 2026, its #80 holding.
- Lord, Abbett & Co first reported a position in Gilead Sciences in Q2 2013 and has held it in 33 quarters since.
- Lord, Abbett & Co's Gilead Sciences position peaked at $279M in Q1 2026.
- 2,268 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.
Based on Lord, Abbett & Co's 13F filing for Q2 2026, filed 14 Aug 2026.